Drug Shortage Report for OCTREOTIDE FOR INJECTABLE SUSPENSION

Last updated on 2024-04-29 History
Report ID 166972
Drug Identification Number 02503778
Brand name OCTREOTIDE FOR INJECTABLE SUSPENSION
Common or Proper name OCTREOTIDE FOR INJ
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) OCTREOTIDE
Strength(s) 20MG
Dosage form(s) POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT
Route of administration INTRAMUSCULAR
Packaging size 1
ATC code H01CB
ATC description HYPOTHALAMIC HORMONES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-08-18
Estimated end date 2024-05-31
Actual end date
Shortage status Actual shortage
Updated date 2024-04-29
Company comments Product under allocation - hospital only
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v17 2024-04-29 French Compare
v16 2024-04-29 English Compare
v15 2024-02-22 French Compare
v14 2024-02-22 English Compare
v13 2023-04-24 French Compare
v12 2023-04-24 English Compare
v11 2023-02-02 French Compare
v10 2023-02-02 English Compare
v9 2022-09-22 French Compare
v8 2022-09-22 English Compare
v7 2022-08-19 English Compare
v6 2022-08-18 French Compare
v5 2022-08-18 English Compare
v4 2022-08-18 French Compare
v3 2022-08-18 English Compare
v2 2022-08-18 French Compare
v1 2022-08-18 English Compare

Showing 1 to 17 of 17